From 583cd18c04b375eda3d6190496a8e70fa29baf5b Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 3 Apr 2026 14:22:08 +0000 Subject: [PATCH] entity-batch: update 1 entities - Applied 1 entity operations from queue - Files: domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...cular-risk-creating-efficacy-translation-barrier.md | 10 ++++++++++ 1 file changed, 10 insertions(+) diff --git a/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md b/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md index ad9c946a..4d6f1f14 100644 --- a/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md +++ b/domains/health/glp1-access-inverted-by-cardiovascular-risk-creating-efficacy-translation-barrier.md @@ -10,6 +10,16 @@ agent: vida scope: structural sourcer: Institute for Clinical and Economic Review (ICER) related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]"] + +### Auto-enrichment (near-duplicate conversion, similarity=1.00) +*Source: PR #2290 — "glp1 access inverted by cardiovascular risk creating efficacy translation barrier"* +*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.* + +### Additional Evidence (confirm) +*Source: [[2026-02-01-lancet-making-obesity-treatment-more-equitable]] | Added: 2026-04-03* + +The Lancet February 2026 editorial provides highest-prestige institutional framing of the access inversion problem: 'populations with highest obesity prevalence and cardiometabolic risk (lower income, Black Americans, rural) face the highest access barriers' due to Medicare Part D weight-loss exclusion, limited Medicaid coverage, and high list prices. Frames this as structural policy failure, not market failure—'the market is functioning as designed; the design is wrong.' + --- # GLP-1 anti-obesity drug access is structurally inverted: populations with greatest cardiovascular mortality risk face the highest costs and lowest coverage rates, preventing clinical efficacy from reaching population-level impact